Inhibikase Therapeutics Inc
NASDAQ:IKT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Inhibikase Therapeutics Inc
Inhibikase Therapeutics Inc
Depreciation & Amortization
Inhibikase Therapeutics Inc
Depreciation & Amortization Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive Depreciation & Amortization Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Inhibikase Therapeutics Inc
NASDAQ:IKT
|
Depreciation & Amortization
$174k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
37%
|
CAGR 10-Years
26%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
$2.7B
|
CAGR 3-Years
20%
|
CAGR 5-Years
14%
|
CAGR 10-Years
18%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
$4.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$196m
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$435.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
26%
|
See Also
What is Inhibikase Therapeutics Inc's Depreciation & Amortization?
Depreciation & Amortization
174k
USD
Based on the financial report for Mar 31, 2024, Inhibikase Therapeutics Inc's Depreciation & Amortization amounts to 174k USD.
What is Inhibikase Therapeutics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 1Y
770%
Over the last year, the Depreciation & Amortization growth was 770%.
You don't have any saved screeners yet
